Skip to main content
Erschienen in: Journal of Neurology 7/2020

13.03.2020 | Original Communication

GCH-1 genetic variant may cause Parkinsonism by unmasking the subclinical nigral pathology

verfasst von: Jung Hwan Shin, Woong-Woo Lee, Jee-Young Lee, Han-Joon Kim, Beomseok Jeon

Erschienen in: Journal of Neurology | Ausgabe 7/2020

Einloggen, um Zugang zu erhalten

Abstract

Background

Recent studies suggest that GTP cyclohydrolase 1 (GCH-1) variant may be a risk factor for nigral degeneration causing PD.

Methods

A 49-year-old Korean woman visited our movement disorder clinic with the initial presentation of Parkinsonism starting at age 47. We monitored the degree of nigral degeneration with serial FP-CIT PET throughout the course of her disease (2, 8 and 11 years from disease onset).

Results

The initial clinical presentation was consistent with intrinsic dopamine deficiency caused by GCH-1 variant. However, her follow-up disease course was consistent with Parkinsonism caused by nigral neurodegeneration. We found a novel GCH-1 variant in the current case. The disease course of the patient was overall benign in motor and non-motor aspects, corresponding to previously reported GCH-1 cases with PD. Serial FP-CIT PET scans showed normal initial FP-CIT binding followed by a continuous decline of the putaminal binding ratio. However, the decreased binding ratio could not sufficiently explain the corresponding clinical duration of the patient. Therefore, dopamine deficiency by GCH-1 genetic variant contributed to Parkinsonism in the current case with subclinical nigral degeneration.

Conclusion

Our case suggests that GCH-1 variant causes Parkinsonism by unmasking the subclinical nigral pathology, not by causing the nigral neurodegeneration.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
1.
Zurück zum Zitat Jeon BS, Jeong JM, Park SS, Lee MC (1998) Dopa-responsive dystonia: a syndrome of selective nigrostriatal dopamine deficiency. Adv Neurol 78:309–317PubMed Jeon BS, Jeong JM, Park SS, Lee MC (1998) Dopa-responsive dystonia: a syndrome of selective nigrostriatal dopamine deficiency. Adv Neurol 78:309–317PubMed
2.
5.
Zurück zum Zitat Yoshino H, Nishioka K, Li Y, Oji Y, Oyama G, Hatano T, Machida Y, Shimo Y, Hayashida A, Ikeda A, Mogushi K, Shibagaki Y, Hosaka A, Iwanaga H, Fujitake J, Ohi T, Miyazaki D, Sekijima Y, Oki M, Kusaka H, Fujimoto KI, Ugawa Y, Funayama M, Hattori N (2018) GCH1 mutations in dopa-responsive dystonia and Parkinson's disease. J Neurol 265(8):1860–1870. https://doi.org/10.1007/s00415-018-8930-8 CrossRefPubMed Yoshino H, Nishioka K, Li Y, Oji Y, Oyama G, Hatano T, Machida Y, Shimo Y, Hayashida A, Ikeda A, Mogushi K, Shibagaki Y, Hosaka A, Iwanaga H, Fujitake J, Ohi T, Miyazaki D, Sekijima Y, Oki M, Kusaka H, Fujimoto KI, Ugawa Y, Funayama M, Hattori N (2018) GCH1 mutations in dopa-responsive dystonia and Parkinson's disease. J Neurol 265(8):1860–1870. https://​doi.​org/​10.​1007/​s00415-018-8930-8 CrossRefPubMed
6.
Zurück zum Zitat Kikuchi A, Takeda A, Fujihara K, Kimpara T, Shiga Y, Tanji H, Nagai M, Ichinose H, Urano F, Okamura N, Arai H, Itoyama Y (2004) Arg(184)His mutant GTP cyclohydrolase I, causing recessive hyperphenylalaninemia, is responsible for dopa-responsive dystonia with parkinsonism: a case report. Mov Disord 19(5):590–593. https://doi.org/10.1002/mds.10712 CrossRefPubMed Kikuchi A, Takeda A, Fujihara K, Kimpara T, Shiga Y, Tanji H, Nagai M, Ichinose H, Urano F, Okamura N, Arai H, Itoyama Y (2004) Arg(184)His mutant GTP cyclohydrolase I, causing recessive hyperphenylalaninemia, is responsible for dopa-responsive dystonia with parkinsonism: a case report. Mov Disord 19(5):590–593. https://​doi.​org/​10.​1002/​mds.​10712 CrossRefPubMed
7.
Zurück zum Zitat Tassin J, Durr A, Bonnet AM, Gil R, Vidailhet M, Lucking CB, Goas JY, Durif F, Abada M, Echenne B, Motte J, Lagueny A, Lacomblez L, Jedynak P, Bartholome B, Agid Y, Brice A (2000) Levodopa-responsive dystonia. GTP cyclohydrolase I or parkin mutations? Brain 123(Pt6):1112–1121CrossRefPubMed Tassin J, Durr A, Bonnet AM, Gil R, Vidailhet M, Lucking CB, Goas JY, Durif F, Abada M, Echenne B, Motte J, Lagueny A, Lacomblez L, Jedynak P, Bartholome B, Agid Y, Brice A (2000) Levodopa-responsive dystonia. GTP cyclohydrolase I or parkin mutations? Brain 123(Pt6):1112–1121CrossRefPubMed
10.
Zurück zum Zitat Hjermind LE, Johannsen LG, Blau N, Wevers RA, Lucking CB, Hertz JM, Friberg L, Regeur L, Nielsen JE, Sorensen SA (2006) Dopa-responsive dystonia and early-onset Parkinson's disease in a patient with GTP cyclohydrolase I deficiency? Mov Disord 21(5):679–682. https://doi.org/10.1002/mds.20773 CrossRefPubMed Hjermind LE, Johannsen LG, Blau N, Wevers RA, Lucking CB, Hertz JM, Friberg L, Regeur L, Nielsen JE, Sorensen SA (2006) Dopa-responsive dystonia and early-onset Parkinson's disease in a patient with GTP cyclohydrolase I deficiency? Mov Disord 21(5):679–682. https://​doi.​org/​10.​1002/​mds.​20773 CrossRefPubMed
12.
Zurück zum Zitat Mencacci NE, Isaias IU, Reich MM, Ganos C, Plagnol V, Polke JM, Bras J, Hersheson J, Stamelou M, Pittman AM, Noyce AJ, Mok KY, Opladen T, Kunstmann E, Hodecker S, Munchau A, Volkmann J, Samnick S, Sidle K, Nanji T, Sweeney MG, Houlden H, Batla A, Zecchinelli AL, Pezzoli G, Marotta G, Lees A, Alegria P, Krack P, Cormier-Dequaire F, Lesage S, Brice A, Heutink P, Gasser T, Lubbe SJ, Morris HR, Taba P, Koks S, Majounie E, Raphael Gibbs J, Singleton A, Hardy J, Klebe S, Bhatia KP, Wood NW, International Parkinson's Disease Genomics C, consortium UC-e (2014) Parkinson's disease in GTP cyclohydrolase 1 mutation carriers. Brain 137(Pt 9):2480–2492. https://doi.org/10.1093/brain/awu179 CrossRefPubMedPubMedCentral Mencacci NE, Isaias IU, Reich MM, Ganos C, Plagnol V, Polke JM, Bras J, Hersheson J, Stamelou M, Pittman AM, Noyce AJ, Mok KY, Opladen T, Kunstmann E, Hodecker S, Munchau A, Volkmann J, Samnick S, Sidle K, Nanji T, Sweeney MG, Houlden H, Batla A, Zecchinelli AL, Pezzoli G, Marotta G, Lees A, Alegria P, Krack P, Cormier-Dequaire F, Lesage S, Brice A, Heutink P, Gasser T, Lubbe SJ, Morris HR, Taba P, Koks S, Majounie E, Raphael Gibbs J, Singleton A, Hardy J, Klebe S, Bhatia KP, Wood NW, International Parkinson's Disease Genomics C, consortium UC-e (2014) Parkinson's disease in GTP cyclohydrolase 1 mutation carriers. Brain 137(Pt 9):2480–2492. https://​doi.​org/​10.​1093/​brain/​awu179 CrossRefPubMedPubMedCentral
14.
Zurück zum Zitat Gibb WR, Narabayashi H, Yokochi M, Iizuka R, Lees AJ (1991) New pathologic observations in juvenile onset parkinsonism with dystonia. Neurology 41(6):820–822CrossRefPubMed Gibb WR, Narabayashi H, Yokochi M, Iizuka R, Lees AJ (1991) New pathologic observations in juvenile onset parkinsonism with dystonia. Neurology 41(6):820–822CrossRefPubMed
15.
Zurück zum Zitat Segawa M, Nomura Y, Yukishita S, Nishiyama N, Yokochi M (2004) Is phenotypic variation of hereditary progressive dystonia with marked diurnal fluctuation/dopa-responsive dystonia (HPD/DRD) caused by the difference of the locus of mutation on the GTP cyclohydrolase 1 (GCH-1) gene? Adv Neurol 94:217–223PubMed Segawa M, Nomura Y, Yukishita S, Nishiyama N, Yokochi M (2004) Is phenotypic variation of hereditary progressive dystonia with marked diurnal fluctuation/dopa-responsive dystonia (HPD/DRD) caused by the difference of the locus of mutation on the GTP cyclohydrolase 1 (GCH-1) gene? Adv Neurol 94:217–223PubMed
16.
Zurück zum Zitat Nalls MA, Pankratz N, Lill CM, Do CB, Hernandez DG, Saad M, DeStefano AL, Kara E, Bras J, Sharma M, Schulte C, Keller MF, Arepalli S, Letson C, Edsall C, Stefansson H, Liu X, Pliner H, Lee JH, Cheng R, International Parkinson's Disease Genomics C, Parkinson's Study Group Parkinson's Research: The Organized GI, andMe, GenePd, NeuroGenetics Research C, Hussman Institute of Human G, Ashkenazi Jewish Dataset I, Cohorts for H, Aging Research in Genetic E, North American Brain Expression C, United Kingdom Brain Expression C, Greek Parkinson's Disease C, Alzheimer Genetic Analysis G, Ikram MA, Ioannidis JP, Hadjigeorgiou GM, Bis JC, Martinez M, Perlmutter JS, Goate A, Marder K, Fiske B, Sutherland M, Xiromerisiou G, Myers RH, Clark LN, Stefansson K, Hardy JA, Heutink P, Chen H, Wood NW, Houlden H, Payami H, Brice A, Scott WK, Gasser T, Bertram L, Eriksson N, Foroud T, Singleton AB (2014) Large-scale meta-analysis of genome-wide association data identifies six new risk loci for Parkinson's disease. Nat Genet 46(9):989–993. https://doi.org/10.1038/ng.3043 CrossRefPubMedPubMedCentral Nalls MA, Pankratz N, Lill CM, Do CB, Hernandez DG, Saad M, DeStefano AL, Kara E, Bras J, Sharma M, Schulte C, Keller MF, Arepalli S, Letson C, Edsall C, Stefansson H, Liu X, Pliner H, Lee JH, Cheng R, International Parkinson's Disease Genomics C, Parkinson's Study Group Parkinson's Research: The Organized GI, andMe, GenePd, NeuroGenetics Research C, Hussman Institute of Human G, Ashkenazi Jewish Dataset I, Cohorts for H, Aging Research in Genetic E, North American Brain Expression C, United Kingdom Brain Expression C, Greek Parkinson's Disease C, Alzheimer Genetic Analysis G, Ikram MA, Ioannidis JP, Hadjigeorgiou GM, Bis JC, Martinez M, Perlmutter JS, Goate A, Marder K, Fiske B, Sutherland M, Xiromerisiou G, Myers RH, Clark LN, Stefansson K, Hardy JA, Heutink P, Chen H, Wood NW, Houlden H, Payami H, Brice A, Scott WK, Gasser T, Bertram L, Eriksson N, Foroud T, Singleton AB (2014) Large-scale meta-analysis of genome-wide association data identifies six new risk loci for Parkinson's disease. Nat Genet 46(9):989–993. https://​doi.​org/​10.​1038/​ng.​3043 CrossRefPubMedPubMedCentral
17.
Zurück zum Zitat Lee CS, Samii A, Sossi V, Ruth TJ, Schulzer M, Holden JE, Wudel J, Pal PK, de la Fuente-Fernandez R, Calne DB, Stoessl AJ (2000) In vivo positron emission tomographic evidence for compensatory changes in presynaptic dopaminergic nerve terminals in Parkinson's disease. Ann Neurol 47(4):493–503CrossRefPubMed Lee CS, Samii A, Sossi V, Ruth TJ, Schulzer M, Holden JE, Wudel J, Pal PK, de la Fuente-Fernandez R, Calne DB, Stoessl AJ (2000) In vivo positron emission tomographic evidence for compensatory changes in presynaptic dopaminergic nerve terminals in Parkinson's disease. Ann Neurol 47(4):493–503CrossRefPubMed
20.
Zurück zum Zitat Richards S, Aziz N, Bale S, Bick D, Das S, Gastier-Foster J, Grody WW, Hegde M, Lyon E, Spector E, Voelkerding K, Rehm HL, Committee ALQA (2015) Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. Genet Med 17(5):405–424. https://doi.org/10.1038/gim.2015.30 CrossRefPubMedPubMedCentral Richards S, Aziz N, Bale S, Bick D, Das S, Gastier-Foster J, Grody WW, Hegde M, Lyon E, Spector E, Voelkerding K, Rehm HL, Committee ALQA (2015) Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. Genet Med 17(5):405–424. https://​doi.​org/​10.​1038/​gim.​2015.​30 CrossRefPubMedPubMedCentral
21.
28.
Zurück zum Zitat Jee-Young Lee JWK, Lee WY, Kim JM, Ahn TB, Kim HJ, Cho J, Jeon BS (2010) Daily dose of dopaminergic medications in Parkinson disease: clinical correlates and a posteriori equation. Neurol Asia 15(2):137–143 Jee-Young Lee JWK, Lee WY, Kim JM, Ahn TB, Kim HJ, Cho J, Jeon BS (2010) Daily dose of dopaminergic medications in Parkinson disease: clinical correlates and a posteriori equation. Neurol Asia 15(2):137–143
30.
Zurück zum Zitat Datla KP, Blunt SB, Dexter DT (2001) Chronic L-DOPA administration is not toxic to the remaining dopaminergic nigrostriatal neurons, but instead may promote their functional recovery, in rats with partial 6-OHDA or FeCl(3) nigrostriatal lesions. Mov Disord 16(3):424–434. https://doi.org/10.1002/mds.1091 CrossRefPubMed Datla KP, Blunt SB, Dexter DT (2001) Chronic L-DOPA administration is not toxic to the remaining dopaminergic nigrostriatal neurons, but instead may promote their functional recovery, in rats with partial 6-OHDA or FeCl(3) nigrostriatal lesions. Mov Disord 16(3):424–434. https://​doi.​org/​10.​1002/​mds.​1091 CrossRefPubMed
32.
34.
Zurück zum Zitat Cobb SA, Wider C, Ross OA, Mata IF, Adler CH, Rajput A, Rajput AH, Wu RM, Hauser R, Josephs KA, Carr J, Gwinn K, Heckman MG, Aasly JO, Lynch T, Uitti RJ, Wszolek ZK, Kapatos G, Farrer MJ (2009) GCH1 in early-onset Parkinson's disease. Mov Disord 24(14):2070–2075. https://doi.org/10.1002/mds.22729 CrossRefPubMed Cobb SA, Wider C, Ross OA, Mata IF, Adler CH, Rajput A, Rajput AH, Wu RM, Hauser R, Josephs KA, Carr J, Gwinn K, Heckman MG, Aasly JO, Lynch T, Uitti RJ, Wszolek ZK, Kapatos G, Farrer MJ (2009) GCH1 in early-onset Parkinson's disease. Mov Disord 24(14):2070–2075. https://​doi.​org/​10.​1002/​mds.​22729 CrossRefPubMed
Metadaten
Titel
GCH-1 genetic variant may cause Parkinsonism by unmasking the subclinical nigral pathology
verfasst von
Jung Hwan Shin
Woong-Woo Lee
Jee-Young Lee
Han-Joon Kim
Beomseok Jeon
Publikationsdatum
13.03.2020
Verlag
Springer Berlin Heidelberg
Erschienen in
Journal of Neurology / Ausgabe 7/2020
Print ISSN: 0340-5354
Elektronische ISSN: 1432-1459
DOI
https://doi.org/10.1007/s00415-020-09788-2

Weitere Artikel der Ausgabe 7/2020

Journal of Neurology 7/2020 Zur Ausgabe

Leitlinien kompakt für die Neurologie

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Update Neurologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.